American Brachytherapy Society Task Group Report: Combination of brachytherapy and external beam radiation for high-risk prostate cancer
- PMID: 27771243
- DOI: 10.1016/j.brachy.2016.09.006
American Brachytherapy Society Task Group Report: Combination of brachytherapy and external beam radiation for high-risk prostate cancer
Abstract
Purpose: To review outcomes for high-risk prostate cancer treated with combined modality radiation therapy (CMRT) utilizing external beam radiation therapy (EBRT) with a brachytherapy boost.
Methods and materials: The available literature for high-risk prostate cancer treated with combined modality radiation therapy was reviewed and summarized.
Results: At this time, the literature suggests that the majority of high-risk cancers are curable with multimodal treatment. Several large retrospective studies and three prospective randomized trials comparing CMRT to dose-escalated EBRT have demonstrated superior biochemical control with CMRT. Longer followup of the randomized trials will be required to determine if this will translate to a benefit in metastasis-free survival, disease-specific survival, and overall survival. Although greater toxicity has been associated with CMRT compared to EBRT, recent studies suggest that technological advances that allow better definition and sparing of critical adjacent structures as well as increasing experience with brachytherapy have improved implant quality and the toxicity profile of brachytherapy. The role of androgen deprivation therapy is well established in the external beam literature for high-risk disease, but there is controversy regarding the applicability of these data in the setting of dose escalation. At this time, there is not sufficient evidence for the omission of androgen deprivation therapy with dose escalation in this population. Comparisons with surgery remain limited by differences in patient selection, but the evidence would suggest better disease control with CMRT compared to surgery alone.
Conclusions: Due to a series of technological advances, modern combination series have demonstrated unparalleled rates of disease control in the high-risk population. Given the evidence from recent randomized trials, combination therapy may become the standard of care for high-risk cancers.
Keywords: Combination brachytherapy and external beam radiation; High-risk prostate cancer; Prostate cancer therapy.
Copyright © 2016 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):275-285. doi: 10.1016/j.ijrobp.2016.11.026. Epub 2016 Nov 24. Int J Radiat Oncol Biol Phys. 2017. PMID: 28262473 Clinical Trial.
-
The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.Cancer. 2013 Feb 1;119(3):681-90. doi: 10.1002/cncr.27784. Epub 2012 Aug 14. Cancer. 2013. PMID: 22893254
-
Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1322-31. doi: 10.1016/j.ijrobp.2004.12.053. Int J Radiat Oncol Biol Phys. 2005. PMID: 16029788
-
Dose escalated external beam radiotherapy versus neoadjuvant androgen deprivation therapy and conventional dose external beam radiotherapy for clinically localized prostate cancer: do we need both?Strahlenther Onkol. 2007 Dec;183 Spec No 2:26-8. doi: 10.1007/s00066-007-2011-8. Strahlenther Onkol. 2007. PMID: 18167004 Review.
-
Brachytherapy boost (BT-boost) or stereotactic body radiation therapy boost (SBRT-boost) for high-risk prostate cancer (HR-PCa).Cancer Radiother. 2021 Jun;25(4):400-409. doi: 10.1016/j.canrad.2020.11.004. Epub 2021 Jan 18. Cancer Radiother. 2021. PMID: 33478838
Cited by
-
Polyethylene glycol-based hydrogel rectal spacers for prostate brachytherapy: a systematic review with a focus on technique.World J Urol. 2021 Jun;39(6):1769-1780. doi: 10.1007/s00345-020-03414-6. Epub 2020 Aug 25. World J Urol. 2021. PMID: 32840655 Free PMC article.
-
Comparison of Image-Guided Intensity-Modulated Radiotherapy and Low-dose Rate Brachytherapy with or without External Beam Radiotherapy in Patients with Localized Prostate Cancer.Sci Rep. 2018 Jul 12;8(1):10538. doi: 10.1038/s41598-018-28730-1. Sci Rep. 2018. PMID: 30002393 Free PMC article.
-
Application of Hydrogel Spacer SpaceOAR Vue for Prostate Radiotherapy.Tomography. 2022 Oct 27;8(6):2648-2661. doi: 10.3390/tomography8060221. Tomography. 2022. PMID: 36412680 Free PMC article. Review.
-
Stereotactic Radiation Therapy versus Brachytherapy: Relative Strengths of Two Highly Efficient Options for the Treatment of Localized Prostate Cancer.Cancers (Basel). 2022 Apr 29;14(9):2226. doi: 10.3390/cancers14092226. Cancers (Basel). 2022. PMID: 35565355 Free PMC article. Review.
-
Predicting toxicity caused by high-dose-rate brachytherapy single boost for prostate cancer.J Contemp Brachytherapy. 2022 Feb;14(1):7-14. doi: 10.5114/jcb.2022.113545. Epub 2022 Feb 18. J Contemp Brachytherapy. 2022. PMID: 35233229 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical